AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02087293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm - automated call and phone-based pharmacist counseling
Description: patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
Study NCT01738685 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Education.
Study NCT04396795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.
Study NCT04396795 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Each injection session will consist of a total of 5 mL saline solution infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum
Study NCT03536325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Participants will receive Dose 1 of guselkumab on Day 1.
Study NCT03536325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Participants will receive Dose 2 of guselkumab on Day 1.
Study NCT03536325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 3
Description: Participants will receive Dose 3 of guselkumab on Day 1.
Study NCT03536325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo on Day 1.
Study NCT02988726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT01973010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
Study NCT01973010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
Study NCT02517398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C
Description: Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
Study NCT01467466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV isotonic saline
Description: The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
Study NCT01467466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV isotonic bicarbonate
Description: The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
Study NCT01467466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
Study NCT01467466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
Study NCT04426773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Definition transcranial direct current stimulation
Description: The tDCS device will deliver a direct current of 1.5mA for 20 minutes. Cathode electrode will be localized in front of the OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8).
Study NCT01530646 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss
Description: -750kcal/d
Study NCT01530646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: -750kcal/d
Study NCT01530646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy
Description: 2 x 25g/d SPC
Study NCT01530646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 2 x 25g/d WPI
Study NCT00553410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
Study NCT00553410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
Study NCT05009576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silver alginate
Description: silver alginate hydrofiber dressing
Study NCT05009576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VAC dressing without silver alginate
Description: vaccum assisted dressing
Study NCT04619667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula (HFNC)
Description: HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
Study NCT03682406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS-G
Description: Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
Study NCT03682406 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAMS-G
Description: Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
Study NCT04619667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet
Study NCT01513863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Topical Gel 1%
Description: Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
Study NCT04149171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.
Description: The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
Study NCT04149171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: standard treatment based on crystalloid fluid and tranexamic acid (TXA)
Study NCT02812238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR)
Description: NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
Study NCT02812238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
Study NCT03672851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD123 CAR-T treatment
Description: Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
Study NCT00124969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 10mg
Study NCT00124969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg
Study NCT03409952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaseMD and DUAL 1927nm Laser
Description: Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
Study NCT03409952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaseMD
Description: Laser treatment of benign pigmented lesion using optimized treatment settings.
Study NCT00776542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg Tablets
Study NCT00776542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline 100mg Tablets
Study NCT02409641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolatehydrochloride 0,5% eye drops
Description: 1 drop in study eye
Study NCT02110485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Activation Tool
Description: An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
Study NCT01513863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Topical Gel 1% (Metrogel)
Description: Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
Study NCT04808713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
Study NCT01191515 — intervention group
Intervention type: DEVICE
Intervention: Monofocal Intraocular Lenses
Description: Monofocal Intraocular Lenses
Study NCT03123900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
Study NCT03123900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
Study NCT03123900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined training
Description: Subjects included in this group receive both types of intervention.
Study NCT04671563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate 300 MG
Description: One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
Study NCT04671563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate 300 MG
Description: One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
Study NCT01513863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied to affected area once a day for 70 days
Study NCT02790294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
Study NCT01443182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STAIR
Description: Skills Training in Affective and Interpersonal Regulation
Study NCT01443182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAIR
Description: Skills Training in Affective and Interpersonal Regulation
Study NCT01443182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MPE
Description: Modified prolonged exposure (MPE)
Study NCT02855112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose derived mesenchymal stem cell
Description: Allogeneic Adipose derived Mesenchymal Stem cell transplant
Study NCT00891761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
Study NCT00891761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
Study NCT00891761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV casopitant (placebo)
Description: IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
Study NCT00891761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV casopitant (active)
Description: Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
Study NCT00891761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
Study NCT00891761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
Study NCT01525056 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: ct and mri scans
Description: ct and mri scan preradiation and postradiation
Study NCT01525056 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: ct, mri and pet scan
Description: ct, mri and pet scans preradiation and postradiation
Study NCT01331226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone counseling 1 session
Description: 1 session of telephone counseling
Study NCT01331226 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: written materials only
Description: written materials only
Study NCT01908543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate 200mg oral tablet
Description: Administration by mouth
Study NCT02408679 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
Study NCT02408679 — intervention group
Intervention type: OTHER
Intervention: Predictive questionnaire for vitamin D insufficiency
Description: The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
Study NCT01740258 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT01740258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT01740258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02131311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable, single-use pessary
Study NCT01479764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
Study NCT01479764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: neostigmine, per usual practice
Study NCT01479764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: glycopyrrolate per usual practice
Study NCT03255889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Tridecanoate
Description: Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).
Study NCT03255889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sunflower oil emulsion of equal calories.
Study NCT01443182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMDR
Description: Eye movement desensitization and reprocessing
Study NCT03775629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polmacoxib and Tramadol combination
Description: Tramadol hydrochloride , Polmacoxib
Study NCT03775629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polmacoxib
Description: Polmacoxib
Study NCT03775629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride
Description: Tramadol hydrochloride (HCl)
Study NCT03802760 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Doppler (TCD) ultrasound measurement
Description: Non-invasive measurement of cerebral embolic load and blood flow using TCD
Study NCT03385564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection
Study NCT01525056 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: ct, mri and pet scans
Description: single arm with ct, mri and pet scans pre and post radiation
Study NCT01221818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 25mg single dose or matching placebo
Study NCT02286310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetic Chain Exercises
Description: Exercises include kinetic chain segments.
Study NCT02286310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercises
Description: Stretching, strengthening exercises.
Study NCT02593682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Study NCT02593682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo